Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Clinico-Radiological Features of Tumor-like Lesions of the Upper Limbs: don’t worry about those lumps

Author(s): Federico Ponti *, Elena Borlandelli, Antonio De Cinque , Andrea Sambri , Massimiliano De Paolis, Roberto Rotini and Alessandro Marinelli

Volume 17, Issue 2, 2021

Published on: 11 January, 2021

Page: [244 - 260] Pages: 17

DOI: 10.2174/1573405617666210111103537

Price: $65

Abstract

Tumor-like lesions of the upper limb are more frequent than malignant neoplastic lesions and they represent a wide and heterogeneous group of disorders. The combination of clinical evaluation and imaging is the first pivotal step to attempt a distinction between benign and malignant masses, since there are important implications for further management, such as the requirement for conservative or interventional treatment. The classification of these pseudo tumoral lumps remains arbitrary and is still a matter of debate, currently based on a conjunct clinico-radiologic approach. In this article, we review various types of tumor-like lesions of the upper limb in terms of imaging approach and related clinic features, proponing a descriptive classification, useful in clinical practice to recognize these disorders, and to avoid unnecessary or potentially harmful procedures.

Keywords: Upper extremity, ganglion cysts, tumor-like lesions, differential diagnosis, bursitis, wrist joint, hand, shoulder, magnetic resonance imaging, ultrasonography.

Graphical Abstract

[1]
Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S. French Endocrinology Society non-functioning pituitary adenoma work-group. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris) 2015; 76(3): 239-47.
[http://dx.doi.org/10.1016/j.ando.2015.04.002] [PMID: 26072284]
[2]
Chen L, White WL, Spetzler RF, Xu B. A prospective study of nonfunctioning pituitary adenomas: Presentation, management, and clinical outcome. J Neurooncol 2011; 102(1): 129-38.
[http://dx.doi.org/10.1007/s11060-010-0302-x] [PMID: 20730474]
[3]
Karavitaki N, Collison K, Halliday J, et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 2007; 67(6): 938-43.
[http://dx.doi.org/10.1111/j.1365-2265.2007.02990.x] [PMID: 17692109]
[4]
Daems T, Verhelst J, Michotte A, Abrams P, De Ridder D, Abs R. Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary 2009; 12(1): 80-6.
[http://dx.doi.org/10.1007/s11102-008-0085-7] [PMID: 18350381]
[5]
Lloyd R, Osamura R, Klöppel G, Rosai J, Eds. World Health Organization Classification of Tumours of Endocrine Organs. 4th ed. Lyon, France: IARC Publication 2017; Vol. 10.
[6]
Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007; 156(2): 203-16.
[http://dx.doi.org/10.1530/eje.1.02326] [PMID: 17287410]
[7]
Chiloiro S, Doglietto F, Trapasso B, et al. Typical and atypical pituitary adenomas: A single-center analysis of outcome and prognosis. Neuroendocrinology 2015; 101(2): 143-50.
[http://dx.doi.org/10.1159/000375448] [PMID: 25633744]
[8]
Kasuki L, Antunes X, Coelho MCA, et al. Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas. Clin Endocrinol (Oxf) 2020; 92(2): 145-9.
[http://dx.doi.org/10.1111/cen.14133] [PMID: 31773787]
[9]
Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 2010; 95(9): 4268-75.
[http://dx.doi.org/10.1210/jc.2010-0537] [PMID: 20534753]
[10]
Sakharova AA, Dimaraki EV, Chandler WF, Barkan AL. Clinically silent somatotropinomas may be biochemically active. J Clin Endocrinol Metab 2005; 90(4): 2117-21.
[http://dx.doi.org/10.1210/jc.2004-0875] [PMID: 15671111]
[11]
Ferrante E, Ferraroni M, Castrignanò T, et al. Non-functioning pituitary adenoma database: A useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 2006; 155(6): 823-9.
[http://dx.doi.org/10.1530/eje.1.02298] [PMID: 17132751]
[12]
Freda PU, Beckers AM, Katznelson L, et al. Endocrine Society. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(4): 894-904.
[http://dx.doi.org/10.1210/jc.2010-1048] [PMID: 21474686]
[13]
Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33(4): 610-7.
[http://dx.doi.org/10.1227/00006123-199310000-00008] [PMID: 8232800]
[14]
Raverot G, Vasiljevic A, Jouanneau E. Prognostic factors of regrowth in nonfunctioning pituitary tumors. Pituitary 2018; 21(2): 176-82.
[http://dx.doi.org/10.1007/s11102-017-0861-3] [PMID: 29288467]
[15]
Cortet-Rudelli C, Bonneville J-F, Borson-Chazot F, et al. Post-surgical management of non-functioning pituitary adenoma. Ann Endocrinol (Paris) 2015; 76(3): 228-38.
[http://dx.doi.org/10.1016/j.ando.2015.04.003] [PMID: 26116412]
[16]
Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab 2012; 26(4): 447-60.
[http://dx.doi.org/10.1016/j.beem.2012.01.002] [PMID: 22863387]
[17]
Ghazi AA, Rotondo F, Kovacs K, et al. Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature. Endocr Pathol 2015; 26(2): 135-9.
[http://dx.doi.org/10.1007/s12022-015-9361-z] [PMID: 25716461]
[18]
Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr. Atypical pituitary adenomas: Incidence, clinical characteristics, and implications. J Neurosurg 2011; 114(2): 336-44.
[http://dx.doi.org/10.3171/2010.8.JNS10290] [PMID: 20868211]
[19]
Raverot G, Assié G, Cotton F, et al. Biological and radiological exploration and management of non-functioning pituitary adenoma. Ann Endocrinol (Paris) 2015; 76(3): 201-9.
[http://dx.doi.org/10.1016/j.ando.2015.04.005] [PMID: 26122495]
[20]
Chinezu L, Jouanneau E, Vasiljevic A, Trouillas J, Raverot G. Silent GH pituitary tumor: Diagnostic and therapeutic challenges. Ann Endocrinol (Paris) 2013; 74(5-6): 491-5.
[http://dx.doi.org/10.1016/j.ando.2013.09.003] [PMID: 24262981]
[21]
Wade AN, Baccon J, Grady MS, Judy KD, O’Rourke DM, Snyder PJ. Clinically silent somatotroph adenomas are common. Eur J Endocrinol 2011; 165(1): 39-44.
[http://dx.doi.org/10.1530/EJE-11-0216] [PMID: 21493729]
[22]
Lamas C, García-Martínez A, Cámara R, Fajardo-Montanana C, Viguera L, Aranda I. Silent somatotropinomas. Minerva Endocrinol 2019; 44(2): 137-42.
[http://dx.doi.org/10.23736/S0391-1977.18.02946-2] [PMID: 30531696]
[23]
Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol 2017; 176(2): 195-201.
[http://dx.doi.org/10.1530/EJE-16-0738] [PMID: 27913611]
[24]
Mohammed S, Syro L, Abad V, et al. Silent somatotroph adenoma of the pituitary in an adolescent. Can J Neurol Sci 2009; 36(1): 123-5.
[http://dx.doi.org/10.1017/S0317167100006466] [PMID: 19294904]
[25]
Kalavalapalli S, Reid H, Kane J, Buckler H, Trainer P, Heald AH. Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess. Ann Clin Biochem 2007; 44(Pt 1): 89-93.
[http://dx.doi.org/10.1258/000456307779596075] [PMID: 17270100]
[26]
Kawaguchi T, Ogawa Y, Tominaga T. Early surgical intervention for patients with possible clinically silent somatotroph adenoma: a case series. J Med Case Reports 2019; 13(1): 85.
[http://dx.doi.org/10.1186/s13256-019-1981-3] [PMID: 30862315]
[27]
Baldeweg SE, Pollock JR, Powell M, Ahlquist J. A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg 2005; 19(1): 38-42.
[http://dx.doi.org/10.1080/02688690500081230] [PMID: 16147581]
[28]
Nishioka H, Inoshita N, Mete O, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 2015; 26(4): 349-55.
[http://dx.doi.org/10.1007/s12022-015-9398-z] [PMID: 26481628]
[29]
Righi A, Faustini-Fustini M, Morandi L, et al. The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3. Endocrine 2017; 56(2): 286-97.
[http://dx.doi.org/10.1007/s12020-016-1028-0] [PMID: 27491554]
[30]
Langlois F, Lim DST, Varlamov E, et al. Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. Endocrine 2017; 58(3): 528-34.
[http://dx.doi.org/10.1007/s12020-017-1447-6] [PMID: 29043561]
[31]
Cho HY, Cho SW, Kim SW, Shin CS, Park KS, Kim SY. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 2010; 72(5): 648-53.
[http://dx.doi.org/10.1111/j.1365-2265.2009.03673.x] [PMID: 19650787]
[32]
Ben-Shlomo A, Cooper O. Silent corticotroph adenomas. Pituitary 2018; 21(2): 183-93.
[http://dx.doi.org/10.1007/s11102-018-0864-8] [PMID: 29344907]
[33]
Guttenberg KB, Mayson SE, Sawan C, et al. Prevalence of clinically silent corticotroph macroadenomas. Clin Endocrinol (Oxf) 2016; 85(6): 874-80.
[http://dx.doi.org/10.1111/cen.13146] [PMID: 27346850]
[34]
Cheres AF, ElAsmar N, Rajpal A, Selman WR, Arafah BM. Perioperative hypothalamic pituitary adrenal function in patients with silent corticotroph adenomas. Pituitary 2017; 20(4): 471-6.
[http://dx.doi.org/10.1007/s11102-017-0809-7] [PMID: 28528397]
[35]
Mete O, Hayhurst C, Alahmadi H, et al. The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. Endocr Pathol 2013; 24(4): 191-8.
[http://dx.doi.org/10.1007/s12022-013-9270-y] [PMID: 24091601]
[36]
Jahangiri A, Wagner JR, Pekmezci M, et al. Comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 2013; 73(1): 8-17.
[37]
Aylwin SJ, Welch JP, Davey CL, et al. The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas. J Clin Endocrinol Metab 2001; 86(6): 2476-83.
[http://dx.doi.org/10.1210/jc.86.6.2476] [PMID: 11397843]
[38]
Ito Y. Unexpected enlargement of clinically silent pituitary gonadotroph adenoma induced by goserelin acetate given as treatment for prostate cancer. Int J Urol 2011; 18(1): 83-4.
[http://dx.doi.org/10.1111/j.1442-2042.2010.02676.x] [PMID: 21077963]
[39]
Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and pathological aspects of silent pituitary adenomas. J Clin Endocrinol Metab 2019; 104(7): 2473-89.
[http://dx.doi.org/10.1210/jc.2018-00688] [PMID: 30020466]
[40]
Øystese KAB, Berg JP, Normann KR, Zucknick M, Casar-Borota O, Bollerslev J. The role of E and N-cadherin in the postoperative course of gonadotroph pituitary tumours. Endocrine 2018; 62(2): 351-60.
[http://dx.doi.org/10.1007/s12020-018-1679-0] [PMID: 30051197]
[41]
Hanson PL, Aylwin SJ, Monson JP, Burrin JM. FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas. Eur J Endocrinol 2005; 152(3): 363-70.
[http://dx.doi.org/10.1530/eje.1.01854] [PMID: 15757852]
[42]
Ho DM, Hsu CY, Ting LT, Chiang H. The clinicopathological characteristics of gonadotroph cell adenoma: A study of 118 cases. Hum Pathol 1997; 28(8): 905-11.
[http://dx.doi.org/10.1016/S0046-8177(97)90005-8] [PMID: 9269826]

Rights & Permissions Print Cite
Article Metrics
18
1
© 2024 Bentham Science Publishers | Privacy Policy